TY - JOUR
T1 - Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
AU - Bayraktar, Ulas D.
AU - Bashir, Qaiser
AU - Qazilbash, Muzaffar
AU - Champlin, Richard E.
AU - Ciurea, Stefan O.
PY - 2013/3
Y1 - 2013/3
N2 - Melphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell transplantation (SCT). From its initial discovery more than 50 years ago, it has been gradually incorporated in the conditioning regimens for both autologous and allogeneic transplantations because of its myeloablative properties and broad antitumor effects as a DNA alkylating agent. Melphalan remains the mainstay conditioning for multiple myeloma and lymphomas, and it has been used successfully in preparative regimens of a variety of other hematological and nonhematological malignancies. The addition of newer agents to conditioning, such as bortezomib or lenalidomide for myeloma or clofarabine for myeloid malignancies, may improve antitumor effects for transplantation, whereas melphalan in combination with alemtuzumab may represent a backbone for future cellular therapy because of reliable engraftment and low toxicity profile. This review summarizes the development and the current use of this remarkable drug in hematopoietic SCT.
AB - Melphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell transplantation (SCT). From its initial discovery more than 50 years ago, it has been gradually incorporated in the conditioning regimens for both autologous and allogeneic transplantations because of its myeloablative properties and broad antitumor effects as a DNA alkylating agent. Melphalan remains the mainstay conditioning for multiple myeloma and lymphomas, and it has been used successfully in preparative regimens of a variety of other hematological and nonhematological malignancies. The addition of newer agents to conditioning, such as bortezomib or lenalidomide for myeloma or clofarabine for myeloid malignancies, may improve antitumor effects for transplantation, whereas melphalan in combination with alemtuzumab may represent a backbone for future cellular therapy because of reliable engraftment and low toxicity profile. This review summarizes the development and the current use of this remarkable drug in hematopoietic SCT.
KW - Conditioning regimens
KW - Melphalan
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=84873713032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873713032&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2012.08.011
DO - 10.1016/j.bbmt.2012.08.011
M3 - Review article
C2 - 22922522
AN - SCOPUS:84873713032
SN - 1083-8791
VL - 19
SP - 344
EP - 356
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 3
ER -